India’s Gennova Biopharmaceuticals is working on an Omicron-specific COVID-19 vaccine candidate that could be ready within a month or two, a person with direct knowledge of the matter told Reuters.
The source, who asked not to be named, said the product may require small trials in India before it can be launched as a booster or stand-alone vaccine.
Representatives for Gennova, a subsidiary of drugmaker Emcure Pharmaceuticals, which operates in about 70 countries, did not immediately respond to a request for comment.
Pfizer Inc said last week that a redesigned COVID-19 vaccine specifically targeting a variant of the Omicron coronavirus could be ready for launch in March.
Gennova separately submitted data from a phase 2 trial of its original mRNA vaccine candidate to India’s drug regulator on Friday, the sources said. The government said last year that the product was found to be “safe, tolerable and immunogenic” among participants in a pilot study.
Complete News Source : Hindustan Times
